Biopharmaceutical company HotSpot acquired Maccroceutics

pharmaceutical company HotSpot Therapeutics has announced its acquisition of Maccroceutics. No financial terms have been announced for this transaction.It is reported that after the completion of the acquisition, Macroceutics' DNA coding compound library (DEL) will be integrated into HotSpot's drug research and development platform SpotFinder. In addition, Dr. Ken Carson, founder and CEO of Macroceutics, will lead the DEL screening team.Macroceutics is a supplier of DNA-coded compound library (DEL) synthesis and screening technologies that help pharmaceutical companies develop new drugs. The concept of DEL synthesis and screening was first proposed by Sidney Breener and Dr. Richard Lerner of the Scripps Institute in the United States. The technology combines combined chemistry and molecular biology and is supported by high-volume sequencing technology. Today, DEL technology can quickly synthesize millions of molecules and screen target proteins, making screening of pilot compounds faster and more efficient.Founded in 2017 and headquartered in Massachusetts, HotSpot is a biotechnology and pharmaceutical company. Led by co-founder and Chief Scientific Officer Dr. Geraldine Harriman, the company is committed to developing drugs for the treatment of severe autoimmune and metabolic diseases. In addition, HotSpot has pioneered new therapies that help patients recover by regulating protein function.HotSpot's SpotFinder platform is primarily used to develop high-precision and high-potency variants. Unlike traditional drug research and development ideas that target protein active points, the platform studies the function of proteins far from active bits. HotSpot says drugs developed based on the SpotFinder platform are both more effective and safe than conventional treatments.HotSpot has developed targeted PKC-gamma variant inhibitors for autoimmune diseases, as well as S6 kinases involved in regulating insulin sensitivity and mitochondrial function in the liver. In addition, the company is exploring new targets for the treatment of metabolic diseases such as non-alcoholic fatty hepatitis (NASH).Variant protein points are difficult to distinguish from other protein points, so the rational development of small molecule drugs for variants has been challenging and requires specialized assay techniques to assess the binding capacity of drug molecules to variants. HotSpot's core mission is to develop new technologies for this challenge and to develop drugs based on the means of controlling protein function.Geraldine Harriman said: "We are delighted to be working with the Maccroceutics team, whose leading DEL technology will provide HotSpot with a wealth of protein molecular information to help us accelerate the development of innovative drugs. Carson , said: "I'm very proud to see Maccroceutics' DEL technology being used in the HotSpot drug development platform. We will work with HotSpot to develop new variant drugs for a wide range of patients. " (Arterial mesh)